Beneficial Effects of Omega-3 Supplement to the Enteral Feeding in Children With Mild to Moderate Sepsis.

What Was Tested

Researchers studied Fatty Acids, Omega-3 in this randomized controlled trial publication.

Who Took Part

According to the abstract, 3 children were involved.

PubMed indexes the participants as young children, both men and women.

The study was a prospective randomized, double-blind, placebo-controlled study from January 2012 to June 2014, which included 2 groups of children with mild to moderate sepsis tolerating enteral feeding.

Group A included 60 children supplemented with omega-3 fatty acids, whereas group B included 60 children who received enteral feeding without omega-3 supplementation.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The children were allocated by chance, so the Fatty Acids, Omega-3 group and the comparison group should start out alike.

As a double-blind Fatty Acids, Omega-3 study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Fatty Acids, Omega-3 could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including C-Reactive Protein, Critical Care, Enteral Nutrition, Fatty Acids, Omega-3, Intensive Care Units, Pediatric, Interleukin-6 and Lymphocyte Activation.

The authors tagged it with the keywords CRP, ESR, children, enteral feeding, interleukin 6 and sepsis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Fatty Acids, Omega-3 in 3 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Journal of intensive care medicine), a journal based in United States.

More context: all human trials.